Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 1/20 | 0.59 |
| ▸ | FLT3 | P36888 | 1/20 | 0.59 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.59 |
| ▸ | AXL | P30530 | 2/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.41 |
| ▸ | CCNC | P24863 | 10/20 | 0.39 |
| ▸ | CDK8 | P49336 | 10/20 | 0.39 |
| ▸ | MET | P08581 | 2/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | PI4KA | P42356 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18999176 | 0.88 | LRRK2 (0.50) | KITFLT3NTRK3LRRK2CCNC | |
| SCHEMBL17469643 | 0.79 | KIT (0.57) | KITFLT3NTRK3 | |
| SCHEMBL17469720 | 0.79 | KIT (0.68) | KITFLT3NTRK3PIK3CDPI4KA | |
| SCHEMBL17469724 | 0.78 | KIT (0.61) | KITFLT3NTRK3LRRK2 | |
| SCHEMBL17469797 | 0.77 | CCNC (0.45) | AXLLRRK2CCNCCDK8MET | |
| SCHEMBL17469613 | 0.76 | KIT (0.64) | KITFLT3NTRK3 | |
| SCHEMBL17469721 | 0.75 | KIT (0.60) | KITFLT3NTRK3 | |
| SCHEMBL17469722 | 0.75 | KIT (0.60) | KITFLT3NTRK3 | |
| SCHEMBL17469725 | 0.75 | KIT (0.60) | KITFLT3NTRK3CCNCCDK8 | |
| SCHEMBL17469645 | 0.74 | KIT (0.59) | KITFLT3NTRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174620-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | UNIVERSITY OF MARYLAND, COLLEGE PARK | 2017-06-22 | — | — | US | disclosed |
| WO-2016014674-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2016-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174620-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | MCL1, DPYD, TOP2B | KIT 2616/4885FLT3 2354/4885NTRK3 4453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.